Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04471935
Other study ID # 1R43DC018771-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 20, 2021
Est. completion date October 20, 2021

Study information

Verified date January 2022
Source Flint Rehabilitation Devices, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators will run an at-home usability study of a newly developed speech therapy app called Speech Hero with 10 individuals with Broca's aphasia in the chronic stage of stroke. The Speech Hero app allows users to perform rhythm-based speech exercises at home. For this study participants will be instructed to use Speech Hero for at least 10 hours over a 4-week period.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date October 20, 2021
Est. primary completion date October 15, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Diagnosis of Broca's aphasia due to stroke, - >6 months post stroke - sufficient motor function of the unaffected upper extremity to tap on a table while speaking Exclusion Criteria: - Incidence of other neurological diseases (though individuals with apraxia will be included) - age <85

Study Design


Related Conditions & MeSH terms


Intervention

Device:
At home Speech Hero therapy app
Participants will be instructed to use the Speech Hero therapy app for three hours per week over a 4-week period.

Locations

Country Name City State
United States Callier Center at University of Texas Dallas Richardson Texas

Sponsors (2)

Lead Sponsor Collaborator
Flint Rehabilitation Devices, LLC University of Texas

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants That Used the Device for at Least Ten Hours Over the Course of Four Weeks Number of participants able to use the device on their own at home for at least 10 hours over four weeks without technical or other issues. Speech Hero will be deemed feasible for this population if at least 5 participants are able to use the device on their own at home for at least 10 hours over four weeks without technical or other issues. Immediately Post-Treatment, an average of 4 weeks
Secondary Change in Score on Western Aphasia Battery Assessment of language function of adults with suspected neurological disorders as a result of a stroke, head injury, or dementia. The Western Aphasia Battery (WAB) is comprised of 8 subscales. For this study the subscales of spontaneous speech, auditory verbal comprehension, repetition, naming and word finding were used. Results reported as change in score from baseline to post-treatment (each subscale score is on 0-100% scale with higher score representing less impairment). Immediately Post-Treatment, an average of 4 weeks
Secondary Change in Score on Boston Naming Test Assessment of language function of adults with suspected neurological disorders as a result of a stroke, head injury, or dementia. Scoring counts the number of spontaneously produced correct responses, the number of cues given, and the number of responses after phonemic cueing and after semantic cueing. Results reported as change in score from baseline to post-treatment (score for Boston Naming Test (BNT) is on 0-100% scale with higher score representing less impairment). Immediately Post-Treatment, an average of 4 weeks